Please note: The information displayed on this page might be outdated.
Maxwell Biosciences: Developer of a novel synthetic biomimic drug class intended to target human virus. The company's virucidal drugs mimic natural antimicrobial peptides and destroy a broad range of viruses directly, irreversibly and permanently inactivating the virus itself. Maxwell drug candidates have direct virucidal action against SARS-CoV-2, the COVID-19 virus. Maxwell's drugs have undergone testing and is effective against Herpes Simplex Virus-1 (HSV-1), Chikungunya, Hepatitis B Virus (HBV ), and Influenza.
US - West South Central
Company Participants at Spring Private Company Showcase
Maxwell Biosciences, CEO
A graduate of the USAF Academy, Joshua has over 18 years of experience as a tech company CEO. He is a multi-patent holder with a background in military and commercial intelligence. His knowledge of leadership principles alongside his 2016 big data study of immune proteins’ impact on health outcomes are the foundation of the company.